Loss of LYN is frequent in targeted-therapy resistant melanoma cells and favors metastatic properties. Gaudel C, Pisibon C, Soysouvanh F, Giuliano S, et al. J Invest Dermatol 2024 Jul 19:S0022-202X(24)01913.

Read + Share

Amedeo Smart

Independent Medical Education

Gaudel C, Pisibon C, Soysouvanh F, Giuliano S, et al. Loss of LYN is frequent in targeted-therapy resistant melanoma cells and favors metastatic properties. J Invest Dermatol 2024 Jul 19:S0022-202X(24)01913.
PMID: 39033988